NCT02243124View on ClinicalTrials.gov

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

cenersen

cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action

DRUG

Dexamethasone

Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Lead Sponsor

Eleos, Inc.
All Listed Sponsors
collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

Eleos, Inc.

INDUSTRY

NCT02243124 - A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter